[1] METINDIR J, GULAY BD. Preoperative hemoglobin and platelet count and poor prognostic factors in patients with endometrial carcinoma[J]. J Cancer Res Clin Oncol, 2009,32(3):125-128. [2] BAMBACE NM, HOLMES CE. The platelet contribution to cancer progression[J]. Journal of Thrombosis and Haemostasis,2011,9(2) :237-249. [3] VOLOSHIN T, VOEST EE, SHAKED Y. The host immunological response to cancer therapy:An emerging concept in tumor biology[J]. Exp Cell Res,2013,319(11):1687-1695. [4] GUNGOR T,KANAT PEKTAS M,SUCAK A,et al. The role of thrombocytosis in prognostic evaluation of epithelial ovarian tumors [J]. Arch Gynecol Obstet,2009,279(1):53-56. [5] BRAHMER JR, TYKODI SS, CHOW LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer[J]. N EngI J Med, 2012, 366(26):2455-2465. [6] LI AJ, MADDEN AC,CASS I,et al. The prognostic significance of thrombocytosis in epithelial ovarian carcinoma[J]. Gynecologic Oncology,2004,9(2):211-214. [7] 庞晓燕,张颐,孟祥凯,等.血小板增多对上皮性卵巢癌预后的影响[J]. 中国医科大学学报,2014,43(9):711-714. [8] STONE RL, NICK AM, MCNEISH LA, et al. Paraneoplastic thrombocytosis in ovarian cancer[J]. N Engl J Med,2012,366(7):610-618. [9] ATACAG T. Diagnostic value of thrombocytosis and high CA-125 level in women with adnexal masses[J]. Eur J Gynaecol Oncol, 2012,33(5):517-520. |